Enof-OZ Tablet is a combination antibiotic formulation containing Ofloxacin 200 mg and Ornidazole 500 mg, designed for the treatment of mixed bacterial and protozoal infections. Ofloxacin, a fluoroquinolone antibiotic, exerts its effect by inhibiting bacterial DNA gyrase and topoisomerase IV, thereby preventing bacterial DNA replication and transcription. Ornidazole, a nitroimidazole derivative, is effective against anaerobic bacteria and protozoa by disrupting DNA synthesis and causing cell death. This synergistic combination is indicated for infections caused by susceptible organisms, including gastrointestinal infections such as amoebiasis, giardiasis, and mixed aerobic and anaerobic bacterial infections of the respiratory tract, genitourinary tract, skin, and soft tissues. Enof-OZ is particularly useful in treating complicated infections where both aerobic and anaerobic pathogens are involved. The tablet should be administered orally as prescribed by a healthcare professional, with dosage adjusted according to the severity of infection and patient response. Caution is advised in patients with hypersensitivity to quinolones or nitroimidazoles, and use during pregnancy and lactation should be under strict medical supervision. Adverse effects may include gastrointestinal disturbances, headache, dizziness, and hypersensitivity reactions. Proper adherence to the prescribed regimen is essential to prevent resistance development.